Wednesday, July 19, 2017

Global Angina Pectoris Treatment Market is expected to reach USD 12,589.6 Mn by 2022- Acute Market ReportAngina Pectoris Treatment Market

"Angina Pectoris Treatment Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2022, the angina pectoris treatment market was valued at USD 7,962.8 Mn in 2015, and is expected to reach USD 12,589.6 Mn by 2022, expanding at a CAGR of 5.2% from 2016 to 2022.
Market Insights
According to American College of Cardiology, Chronic angina affects over seven million North Americans and despite optimal pharmacological and interventional therapies, 32% of these patients remain symptomatic from coronary artery disease (CAD). The market experts suggest that, various approaches have included new pharmacologic antianginal agents, interventional approaches, and therapeutic angiogenesis for treatment of angina pectoris. The beta adrenergic blockers are the first line drugs and the largest drug class segment in angina pectoris treatment market. The major factors assisting growth of beta adrenergic blockers are the efficiency, fast onset of action, accessibility to patients and high patient compliance. A few drugs in phase III of clinical trials are observed as the most potential molecules in the angina pectoris treatment. These potential molecules are such as Dantonic/T89 (Tasly Pharmaceuticals, Inc.), Bococizumab (Pfizer, Inc.), and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). North America angina pectoris treatment market is the largest market globally due to factors such as Rising prevalence of angina pectoris, obesity in young population, sedentary lifestyle, and rising awareness related to early diagnosis of angina pectoris.
Pipeline Analysis
The phase III drugs included in the pipeline analysis are Dantonic/T89 (Tasly Pharmaceuticals, Inc.), RANCAD (TSH Biopharm Corporation Limited), Cilostazol (Korea Otsuka Pharmaceutical Co.,Ltd.), Bococizumab (Pfizer, Inc.), Ticagrelor (J.M. ten Berg/ Astra Zeneca plc), Auto-CD34+ cells (Baxalta US Inc.) and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). Dantonic /T89 is observed as the most potential drug molecule in angina pectoris treatment in the near future. According to Tasly Pharmaceuticals, Inc. the study completion of phase III trial for Dantonic would be by December 2016. According to U.S. National Institutes of Health, Dantonic (T89) is a botanical drug that comprises extracts of Danshen (Radix Salviae Miltiorrhizae) and Sanqi (Radix Notoginseng) with borneol in a capsule form. The drug is currently approved in 26 countries outside the USA for the treatment and prevention of chronic stable angina pectoris and other cardiovascular disease related conditions. This pivotal confirmative Phase III clinical trial is to confirm the efficacy and safety of the drug at 150mg and 225mg doses in the prevention and treatment of angina pectoris in patients with Chronic Stable Angina. Thus, according to its exceptional results projected in phase II suggest that Dantonic would be the most potential pipeline drug for angina pectoris treatement.
Key Market Movements:
• Rising prevalence of angina pectoris due to sedentary lifestyle and obesity in young generation
• High demand for target specific and tailored drugs for angina pectoris treatment
• In developing countries from Asia Pacific and Latin America the awareness related to cardiovascular diseases in increasing"
Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
Chapter 2 Executive Summary
2.1 Global Angina Pectoris Treatment Market Portaiture
2.2 Global Angina Pectoris Treament Market, by Drug Class, 2015 (USD Mn)
2.3 Relativity Analysis: Global Angina Pectoris Treatment Market, by Geography, 2015 & 2022 (USD Mn)
Chapter 3 Angina Pectoris Treatment Market: Market Dynamics and Outlook
3.1 Angina Pectoris Treatment Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Angina Pectoris Treatment Market, 2015 (Value %)
Chapter 4 Global Angina Pectoris Treatment Market, By Drug Class 
4.1 Preface
4.2 Antiplatelet agents
4.3 Beta-adrenergic blocking agents
4.4 Calcium channel blockers
4.5 Short & Long – acting Nitroglycerines
4.6 Angiotensin-converting enzyme inhibitors
4.7 Anti-ischemic agents
4.8 Pipeline Analysis
4.8.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.8.1.1 Dantonic/T89
4.8.1.2 RANCAD
4.8.1.3 Cilostazol
4.8.1.4 Bococizumab
4.8.1.5 Ticagrelor
4.8.1.6 Auto-CD34+ cells
4.8.1.7 Alirocumab
4.8.2 Tabular Representation of Phase II and I Drugs……..
About – Acute Market Reports:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Name: Chris Paul                                               
ACUTE MARKET REPORTS
Designation: Global Sales Manager
Toll Free(US/CANADA): +1-855-455-8662

No comments:

Post a Comment

Global Digital Audio Recorders Market Size, Share, Growth, Outlook and Forecast to 2017: Acute Market Reports

In this report, the  United States Digital Audio Recorders market  is valued at USD XX million in 2016 and is expected to reach USD XX mil...